natgillin/translations-raw huggingface dataset:
Treatment with eltrombopag should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of eltrombopag therapy at 75 mg once daily. 
Liječenje eltrombopagom treba prekinuti ako broj trombocita ne poraste do razine potrebne za sprečavanje klinički značajnog krvarenja nakon 4 tjedna primjene lijeka u dozi od 75 mg jednom dnevno.
Do not re-use the oral dosing syringe. 
Nemojte ponovno koristiti jednom iskorištenu dozirnu štrcaljku za usta.
Unchanged parent compound (eltrombopag) is not detected in urine. 
Nepromijenjeni eltrombopag se ne nalazi u urinu.
12 to 17 years (n=62) 
12 do 17 godina (n=62)
If you don't use the medicine within 30 minutes of mixing it, you will need to mix a new dose. 
Ako ne upotrijebite lijek unutar 30 minuta od kad ste ga zamiješali, morat ćete zamiješati novu dozu.
Eltrombopag was administered to 302 ITP patients in the open-label extension study EXTEND (TRA105325), 218 patients completed 1 year, 180 completed 2 years, 107 completed 3 years, 75 completed 4 years, 34 completed 5 years and 18 completed 6 years. 
Eltrombopag je primijenjen u 302 bolesnika s ITP-om u produžetku otvorenog ispitivanja EXTEND (TRA105325), 218 bolesnika je završilo 1 godinu, 180 je završilo 2 godine, 107 je završilo 3 godine, 75 je završilo 4 godine, 34 je završilo 5 godina i 18 je završilo 6 godina ispitivanja.
Across the programme, no patients had evidence of clinically relevant bone marrow abnormalities or clinical findings that would indicate bone marrow dysfunction. 
Tijekom programa ispitivanja, niti jedan bolesnik nije imao dokazanu klinički značajnu abnormalnost koštane srži ili klinički nalaz koji bi upućivao na disfunkciju koštane srži.
Patients were permitted to reduce or discontinue baseline ITP therapy only during the open-label phase of the study and 53% (8/15) of patients were able to reduce (n=1) or discontinue (n=7) baseline ITP therapy, mainly corticosteroids, without needing rescue therapy. 
Bolesnici su smjeli smanjiti ili prekinuti početnu terapiju za ITP samo tijekom otvorene faze ispitivanja i 53% (8/15) bolesnika moglo je smanjiti (n=1) ili prekinuti (n=7) početnu terapiju za ITP, uglavnom kortikosteroide, bez potrebe za simptomatskom terapijom.
Haemorrhages occurred on the surface of the retina (preretinal), under the retina (subretinal), or within the retinal tissue. 
Krvarenja su se javljala na površini mrežnice (preretinalno), ispod mrežnice (subretinalno) ili unutar samog tkiva mrežnice.
Liver problems (increased enzymes showing up in blood tests) are common and may affect up to 1 in 10 people. 
Jetrene tegobe (povišeni enzimi koji su vidljivi na krvnim pretragama) česta su nuspojava koja se može javiti u do 1 na 10 osoba.
Do not take Revolade 
Nemojte uzimati Revolade
There are no or limited amount of data from the use of eltrombopag in pregnant women. 
Nema podataka ili su podaci o primjeni eltrombopaga u trudnica ograničeni.
Revolade 12.5 mg and 25 mg film-coated tablets also contain polysorbate 80 (E433). 
Revolade 12,5 mg i 25 mg filmom obložene tablete također sadrže i polisorbat 80 (E433).
Empty water into open mixing bottle • Slowly pushing the plunger all the way into the syringe. 
Ispraznite vodu u otvorenu bočicu za miješanje • Polako gurnite klip do kraja u štrcaljku.
Key primary endpoints 
Ključni primarni ishodi ispitivanja
Tell your doctor if any of these apply to you. 
Recite liječniku ako se nešto od navedenog odnosi na Vas.
In studies utilising human liver microsomes, eltrombopag (up to 100 M) showed no in vitro inhibition of the CYP450 enzymes 1A2, 2A6, 2C19, 2D6, 2E1, 3A4/5, and 4A9/11 and was an inhibitor of CYP2C8 and CYP2C9 as measured using paclitaxel and diclofenac as the probe substrates. 
U ispitivanjima na humanim jetrenim mikrosomima eltrombopag (do 100 M) nije pokazao in vitro inhibiciju CYP450 enzima 1A2, 2A6, 2C19, 2D6, 2E1, 3A4/5 i 4A9/11, ali je bio inhibitor CYP2C8 i CYP2C9, mjereno paklitakselom i diklofenakom kao supstratima.
Hepatic decompensation (use with interferon) 
Jetrena dekompenzacija (primjena s interferonom)
HCV study population (in combination with anti-viral interferon and ribavirin therapy) 
Ispitivana populacija s HCV-om (u kombinaciji s antivirusnim liječenjem interferonom i ribavirinom)
TRA108062 (PETIT): The primary endpoint was the proportion of patients achieving platelet counts ≥50,000/µl at least once between weeks 1 and 6 of the randomised period. 
TRA108062 (PETIT): Mjera primarnog ishoda bila je udio bolesnika koji su postigli broj trombocita ≥50 000/µl najmanje jedanput između 1. i 6. tjedna randomiziranog razdoblja.
It is not known whether Revolade passes into breast-milk. 
Nije poznato izlučuje li se Revolade majčinim mlijekom.
The profile of adverse reactions was comparable to that seen in adults with some additional adverse reactions, marked ♦ in the table below. 
Profil nuspojava bio je usporediv s onim uočenim u odraslih, a bile su uočene i neke dodatne nuspojave navedene u tablici u nastavku i označene znakom ♦.
• swelling of the lower limbs due to the accumulation of fluids 
• oticanje donjih udova zbog nakupljanja tekućina
• liver problems, including blood clot, tumour in the liver (see ‘Liver problems' earlier in section 4) 
• jetreni problemi, uključujući krvne ugruške, tumor u jetri (pogledajte „Jetrene tegobe“ ranije u dijelu 4)
Eltrombopag should be discontinued if ALT levels increase (3 times the upper limit of normal [x ULN] in patients with normal liver function, or ≥3 x baseline or >5 x ULN, whichever is the lower, in patients with pre-treatment elevations in transaminases) and are: 
Eltrombopag treba prekinuti ako razina ALT poraste (3 puta iznad gornje granice normale [x GGN] u bolesnika s normalnom funkcijom jetre, ili 3 x od početne vrijednosti ili >5 x GGN, koja god je niža, u bolesnika koji su prije započinjanja terapije imali povišene vrijednosti transaminaza) i ako je porast:
Heart monitoring 
Praćenje rada srca
30 sachets and 1 mixing bottle + 30 single-use oral syringes 
30 vrećica i 1 bočica za miješanje + 30 štrcaljki za usta za jednokratnu uporabu
AUC (0-) and Cmax based on population PK post-hoc estimates at the highest dose in the data for each patient. 
AUC (0-) i Cmax temeljeni na populacijskoj PK post-hoc procjeni pri najvišoj dozi u podacima za svakog bolesnika.
After initiating eltrombopag, the dose must be adjusted to achieve and maintain a platelet count ≥50,000/µl as necessary to reduce the risk for bleeding. 
Nakon uvođenja eltrombopaga, doza lijeka mora biti prilagođena kako bi se postigao i održao broj trombocita ≥50 000/µl, koliko je potrebno da bi se smanjio rizik od nastupa krvarenja.
TPO-R agonists are growth factors that lead to thrombopoietic progenitor cell expansion, differentiation and platelet production. 
Agonisti TPO-R su faktori rasta koji uzrokuju ekspanziju progenitorskih trombopoetskih stanica, njihovu diferencijaciju i stvaranje trombocita.
• Give the entire contents of the bottle to the patient using the same oral syringe. 
• Dajte cijeli sadržaj bočice bolesniku pomoću iste štrcaljke za usta.
Key secondary endpoints Patients with a Day 43 bleeding assessment, n Bleeding (WHO Grades 1-4) n (%) 
Ključni sekundarni ishodi ispitivanja Bolesnici s procjenom krvarenja 43. dana, n Krvarenje (WHO stupanj 1-4), n (%)
Eltrombopag treatment should be terminated when antiviral therapy is discontinued unless otherwise justified. 
Liječenje eltrombopagom treba prekinuti nakon prekidanja antivirusnog liječenja, osim ako drugačije nije opravdano.
• some mineral and vitamin supplements including iron, calcium, magnesium, aluminium, 
• nadomjesne preparate minerala i vitamina koji uključuju željezo, kalcij, magnezij, aluminij,
The diagnosis of ITP or SAA in adults and elderly patients should be confirmed by the exclusion of other clinical entities presenting with thrombocytopenia, in particular the diagnosis of MDS must be excluded. 
Dijagnoza ITP-a ili teške aplastične anemije u odraslih i starijih bolesnika treba biti potvrđena isključivanjem drugih kliničkih stanja koja se prezentiraju trombocitopenijom, a posebno se mora isključiti dijagnozu MDS-a.
The most common adverse reactions occurring in at least 10% of patients included nausea, diarrhoea and increased alanine aminotransferase. 
Najčešće nuspojave koje su se pojavile u najmanje 10% bolesnika uključivale su mučninu, proljev i povišenu alanin aminotransferazu.
Platelet count should be closely monitored in order to ensure appropriate medical management of the dose of eltrombopag when lopinavir/ritonavir therapy is initiated or discontinued. 
Potrebno je pažljivo praćenje broja trombocita kako bi se osigurala primjena odgovarajuće doze eltrombopaga kada se započinje ili prekida liječenje lopinavirom/ritonavirom.
Don't stop taking Revolade without talking to your doctor. 
Nemojte prekinuti uzimanje lijeka Revolade ako se o tome niste posavjetovali sa svojim liječnikom.
30 sachets of powder 
30 vrećica praška
Severe aplastic anaemia in adult patients 
Teška aplastična anemija u odraslih bolesnika
Other secondary findings of the studies included the following: significantly fewer patients treated with eltrombopag prematurely discontinued antiviral therapy compared to placebo (45% vs. 60%, p=<0.0001). 
Druga sekundarna otkrića ispitivanja uključivala su sljedeće: značajno manje bolesnika koji su primali terapiju eltrombopagom je ranije prekinulo antivirusno liječenje u usporedbi s placebom (45% nasuprot 60%, p=<0,0001).
In vitro studies demonstrate that eltrombopag is an inhibitor of the OATP1B1 transporter and an inhibitor of the BCRP transporter and eltrombopag increased exposure of the OATP1B1 and BCRP substrate rosuvastatin in a clinical drug interaction study (see section 4.5). 
In vitro ispitivanja pokazuju da je eltrombopag inhibitor OATP1B1 transportera i inhibitor BCRP transportera i da je eltrombopag povećao izloženost supstrata OATP1B1 i BCRP rosuvastatina u kliničkom ispitivanju interakcije lijekova (vidjeti dio 4.5).
• yellowing of the skin and eyes, tenderness around the liver 
• žutilo kože i očiju, osjetljivost (na dodir) oko jetre
Thrombotic/thromboembolic complications 
Trombotičke/tromboembolijske komplikacije
At Week 12, the proportion of eltrombopag patients reporting any bleeding was decreased to half of baseline (36%). 
U 12. tjednu udio bolesnika na eltrombopagu koji su prijavili bilo kakvo krvarenje smanjen je na polovicu od početnog (36%).
The predominant route of eltrombopag excretion is via faeces (59%) with 31% of the dose found in the urine as metabolites. 
Glavni put izlučivanja je putem stolice (59%), dok se 31% doze nađe u mokraći u obliku metabolita.
What Revolade looks like and contents of the pack Revolade 25 mg powder for oral suspension is available in kits containing 30 sachets; each sachet contains a reddish-brown to yellow powder. 
Revolade 25 mg prašak za oralnu suspenziju dostupan je u kompletima koji sadrže 30 vrećica; svaka vrećica sadrži crvenkasto-smeđi do žuti prašak.
A study in 40 healthy volunteers showed that the co-administration of a single 100 mg dose of eltrombopag with repeat dose lopinavir/ritonavir 400/100 mg twice daily resulted in a reduction in eltrombopag plasma AUCinf by 17% (90% CI: 6.6%, 26.6%). 
Ispitivanje s 40 zdravih dobrovoljaca pokazalo je da istodobna primjena jedne doze eltrombopaga od 100 mg s ponovljenim dozama lopinavira/ritonavira od 400/100 mg dva puta dnevno rezultira smanjenjem plazmatskog AUCinf eltrombopaga za 17% (90% CI: 6,6%, 26,6%).
You may also be checked for the occurrence of any bleeding in or around your retina (the light-sensitive layer of cells at the back of the eye). 
Liječnik će možda također provjeriti postoji li bilo kakvo krvarenje u i oko mrežnice (sloj stanica osjetljivih na svjetlost na stražnjoj strani oka).
Preparation and administration of the powder for oral suspension: 
Priprema i primjena praška za oralnu suspenziju:
In a human radiolabel study, eltrombopag accounted for approximately 64% of plasma radiocarbon AUC0-. 
U ispitivanju kod kojeg je korišten radioaktivno obilježen lijek u ljudi, eltrombopag je bio odgovoran za otprilike 64% AUC0- radioaktivnog ugljika u plazmi.
PETIT2 (TRA115450) was a 2-part, double-blind and open-label, randomised, placebo-controlled study. 
PETIT2 (TRA115450) je bilo ispitivanje u dva dijela, dvostruko slijepo i otvoreno, randomizirano, placebom kontrolirano.
• darkening of the skin 
• tamnjenje kože
In addition, in the RAISE study, 42% of patients with baseline platelet count ≤15,000/μl treated with eltrombopag responded at the end of the 6 month treatment period. 
Osim toga, u RAISE studiji 42% bolesnika s početnim brojem trombocita ≤15 000/μl liječenih eltrombopagom odgovorilo je na kraju šestomjesečnog perioda ispitivanja.
Very common side effects that may show up in blood tests: • increased of liver enzymes (alanine aminotransferase (ALT)) 
Vrlo česte nuspojave koje se vide u krvnim pretragama: porast jetrenih enzima (alanin aminotransferaza (ALT))
• antacid medicines to treat indigestion, heartburn or stomach ulcers (see also ‘When to take it' in section 3) 
• antacidi - lijekovi za liječenje probavnih tegoba, žgaravice ili čira na želucu (također pogledajte „Kada uzeti lijek“ u dijelu 3.)
Cohort 1 (12 to 17 years) 
Kohorta 1 (12 do 17 godina)
There are no PK data on the use of eltrombopag in patients ≥75 years. 
Ne postoje farmakokinetički podatci o korištenju eltrombopaga u bolesnika ≥75 godina.
In clinical studies, platelet counts generally increased within 1 to 2 weeks after starting eltrombopag and decreased within 1 to 2 weeks after discontinuation. 
U kliničkim ispitivanjima broj trombocita obično se povisio unutar 1 do 2 tjedna nakon započinjanja liječenja eltrombopagom te se smanjio unutar 1 do 2 tjedna nakon prestanka uzimanja.
The following additional side effects have been reported to be associated with treatment with Revolade in children (aged 1 to 17 years) with ITP: 
Za sljedeće nuspojave zabilježeno je da su povezane s liječenjem lijekom Revolade u djece (u dobi od 1 do 17 godina) s ITP-om:
Multilineage responses were reported by 45% of patients. 
U 45% bolesnika zabilježeni su odgovori u više loza.
In 3 controlled and 2 uncontrolled clinical studies among adult ITP patients receiving eltrombopag (n=446), 17 patients experienced a total of 19 TEEs, which included (in descending order of occurrence) deep vein thrombosis (n=6), pulmonary embolism (n=6), acute myocardial infarction (n=2), cerebral infarction (n=2), embolism (n=1) (see section 4.4). 
U 3 kontrolirana i 2 nekontrolirana klinička ispitivanja, među odraslim bolesnicima s ITP-om koji su primali eltrombopag (n=446), 17 bolesnika je doživjelo ukupno 19 TED, koji su uključivali (navedeni prema padajućem redoslijedu pojavljivanja): duboku vensku trombozu (n=6), plućnu emboliju (n=6), akutni infarkt miokarda (n=2), cerebralni infarkt (n=2), emboliju (n=1) (vidjeti dio 4.4).
Platelet count should be monitored at least weekly for 2 to 3 weeks when eltrombopag is co-administered with ciclosporin. 
Potrebno je praćenje broja trombocita najmanje jednom tjedno tijekom 2 do 3 tjedna kada se eltrombopag istodobno primjenjuje s ciklosporinom.
This decrease of exposure was attenuated when a single 25 mg dose of eltrombopag powder for oral suspension was administered 2 hours before a high-calcium meal (mean AUC0-∞ was decreased by 20% and mean Cmax by 14%). 
To smanjenje izloženosti bilo je ublaženo kada je jednokratna doza od 25 mg eltrombopag praška za oralnu suspenziju bila primijenjena 2 sata prije obroka s visokim udjelom kalcija (srednji AUC0-∞ bio je smanjen za 20%, a srednji Cmax za 14%).
Statistically fewer eltrombopag patients required rescue treatment during the randomised period compared to placebo patients (19% [12/63] vs. 24% [7/29], p=0.032). 
Statistički manje bolesnika na eltrombopagu trebalo je simptomatsku terapiju tijekom randomiziranog razdoblja u usporedbi s bolesnicima na placebu (19% [12/63] vs. 24% [7/29], p=0,032).
In the pre-antiviral treatment phase, patients received open-label eltrombopag to increase the platelet count to ≥90,000/µl for ENABLE 1 and ≥100,000/µl for ENABLE 2. 
U fazi prije antivirusnog liječenja, bolesnici su otvoreno primali eltrombopag kako bi povećali broj trombocita na ≥90 000/µl u ENABLE 1 i ≥100 000/µl u ENABLE 2 ispitivanju.
• Place the tip of the syringe into the inside of the child's cheek. 
• Postavite vršak štrcaljke djetetu s unutarnje strane obraza.
In contrast, the administration of eltrombopag 2 hours before or 4 hours after a high-calcium meal or with low-calcium food [<50 mg calcium] did not alter plasma eltrombopag exposure to a clinically significant extent (see section 4.2). 
Nasuprot tome, primjena eltrombopaga 2 sata prije ili 4 sata nakon obroka s visokim udjelom kalcija ili s hranom s niskim udjelom kalcija [< 50 mg kalcija] nije promijenila plazmatsku razinu eltrombopaga u klinički značajnoj mjeri (vidjeti dio 4.2).
Based on urinary excretion and metabolites eliminated in faeces, the oral absorption of drug-related material following administration of a single 75 mg eltrombopag solution dose was estimated to be at least 52%. 
Na temelju izlučivanja mokraćom i metabolita eliminiranih stolicom, oralna apsorpcija lijeka nakon primjene jedne doze otopine eltrombopaga od 75 mg, procijenjena je da iznosi barem 52%.
Administration of eltrombopag 75 mg once daily for 7 days to 24 healthy male subjects did not inhibit or induce the metabolism of probe substrates for 1A2 (caffeine), 2C19 (omeprazole), 2C9 (flurbiprofen), or 3A4 (midazolam) in humans. 
Primjena eltrombopaga u dozi od 75 mg jednom dnevno tijekom 7 dana u 24 zdrava muškarca nije inhibirala niti inducirala metabolizam supstrata za 1A2 (kofein), 2C19 (omeprazol), 2C9 (flurbiprofen) ili 3A4 (midazolam) u ljudi.
Uridine diphosphoglucuronyl transferase UGT1A1 and UGT1A3 are responsible for glucuronidation, and bacteria in the lower gastrointestinal tract may be responsible for the cleavage pathway. 
Uridin difosfoglukuronil transferaze UGT1A1 i UGT1A3 su odgovorne za glukuronidaciju, a bakterije u donjem dijelu probavnog sustava bi mogle biti odgovorne za put odstranjivanja cijepanjem.
Dose adjustment is not required when eltrombopag is co-administered with either telaprevir or boceprevir. 
Nije potrebna prilagodba doze kad se eltrombopag primjenjuje istodobno s telaprevirom ili boceprevirom.
Aluminum blisters (PA/Alu/PVC/Alu) in a carton containing 14 or 28 film-coated tablets and multipacks containing 84 (3 packs of 28) film-coated tablets. 
Aluminijski blisteri (PA/Al/PVC/Al) u kutiji koji sadrže 14 ili 28 filmom obloženih tableta i višestruko pakiranje koje sadrži 84 (3 pakiranja po 28) filmom obloženih tableta.
Minor metabolites due to glucuronidation and oxidation were also detected. 
Manje značajni metaboliti nastali glukuronidacijom i oksidacijom su također detektirani.
Paediatric population (aged 1 to 17 years) The safety and efficacy of eltrombopag in paediatric patients have been investigated in two studies. 
Pedijatrijska populacija (u dobi od 1 do 17 godina) Sigurnost i djelotvornost eltrombopaga u pedijatrijskih bolesnika bile su istraživane u dva ispitivanja.
HCV protease inhibitors 
Inhibitori HCV proteaze
For 4 hours before you take 
U razdoblju od 4 sata prije uzimanja lijeka
During antiviral therapy, the dose of eltrombopag should be adjusted as necessary to avoid dose reductions of peginterferon due to decreasing platelet counts that may put patients at risk of bleeding (see Table 2). 
Tijekom antivirusnog liječenja treba po potrebi prilagođavati dozu eltrombopaga kako bi izbjegli smanjivanje doze peginterferona zbog smanjenja broja trombocita koje bi moglo bolesnicima predstavljati rizik za krvarenje (vidjeti tablicu 2).
• infection in the nose, sinuses, throat and upper airways, common cold (upper respiratory tract infection) 
• infekcija u nosu, sinusima, grlu i gornjim dišnim putevima, obična prehlada (infekcija gornjeg dijela dišnog sustava)
The safety and efficacy of eltrombopag has not been established in children and adolescents (<18 years) with chronic HCV related thrombocytopenia or SAA. 
Sigurnost i djelotvornost eltrombopaga u djece i adolescenata (<18 godina) s trombocitopenijom povezanom s kroničnim HCV-om ili teškom aplastičnom anemijom nisu ustanovljene.
• antacids, a type of medicine for indigestion and heartburn 
• antacide, vrstu lijekova za probavne tegobe i žgaravicu
In clinical studies with a TPO-R agonist in patients with MDS, cases of transient increases in blast cell counts were observed and cases of MDS disease progression to acute myeloid leukaemia (AML) were reported. 
U kliničkim ispitivanjima s TPO-R agonistima u bolesnika s MDS-om pronađeni su slučajevi s prolaznim povećanjem broja blasta te postoje izvještaji o slučajevima progresije MDS-a u akutnu mijeloičnu leukemiju (AML).
In the HCV studies the safety population consisted of all randomised patients who received double-blind study medicinal product during Part 2 of ENABLE 1 (Revolade treatment n=450, placebo treatment n=232) and ENABLE 2 (Revolade treatment n=506, placebo treatment n=253). 
U ispitivanjima HCV-a sigurnosnu populaciju su činili svi randomizirani bolesnici koji su primali lijek iz dvostruko slijepog ispitivanja tijekom 2. dijela ENABLE 1 (liječenje Revoladeom n=450, liječenje placebom n=232) i ENABLE 2 ispitivanja (liječenje Revoladeom n=506, liječenje placebom n=253).
There was substantial variability and significant overlap in exposures between patients with hepatic impairment and healthy volunteers. 
Postojala je i značajna varijabilnost i preklapanje u izloženostima između bubrežnih bolesnika i zdravih dobrovoljaca.
For TPO-R agonists there is a concern that they may stimulate the progression of existing haematopoietic malignancies such as MDS. 
Za agoniste TPO-R postoji zabrinutost da bi mogli stimulirati progresiju postojećih hematopoetskih zloćudnih bolesti poput MDS-a.
Patients with these characteristics should be closely monitored for signs and symptoms of hepatic decompensation (see section 4.4). 
Bolesnike s tim karakteristikama treba pažljivo motriti zbog moguće pojave znakova i simptoma jetrene dekompenzacije (vidjeti dio 4.4).
No specific risk factors were identified in those patients who experienced a TEE with the exception of platelet counts ≥200,000/µl (see section 4.4). 
Nisu identificirani specifični čimbenici rizika u bolesnika koji su doživjeli tromboembolijski događaj s iznimkom broja trombocita ≥200 000/µl (vidjeti dio 4.4).
Eltrombopag is absorbed with a peak concentration occurring 2 to 6 hours after oral administration. 
Apsorbirani eltrombopag doseže vršnu koncentraciju 2-6 sati nakon peroralne primjene.
A dose of 100 mg eltrombopag once daily must not be exceeded. 
Ne smije se prekoračiti doza od 100 mg eltrombopaga jednom dnevno.
In vitro studies also demonstrated that eltrombopag is a breast cancer resistance protein (BCRP) substrate and inhibitor (IC50 value of 2.7 μM (1.2 μg/ml). 
In vitro ispitivanja su također pokazala da je eltrombopag supstrat i inhibitor proteina rezistencije raka dojke (BCRP) (IC50 vrijednost od 2,7 μM (1,2 μg/ml).
In the controlled clinical studies in chronic ITP with eltrombopag, increases in serum ALT, AST and bilirubin were observed (see section 4.4). 
U kontroliranim kliničkim ispitivanjima kroničnog ITP-a s eltrombopagom, opažena su povišenja serumskog ALT-a, AST-a i bilirubina (vidjeti dio 4.4).
Make sure the lid is not on the mixing bottle. 
Provjerite da poklopac nije na boci za miješanje.
Eltrombopag must not be used to normalise platelet counts. 
Eltrombopag se ne smije koristiti za normalizaciju broja trombocita.
• increase of liver enzymes (aspartate aminotransferase (AST)) 
• porast jetrenih enzima (aspartat aminotransferaza (AST))
Platelet counts must be monitored weekly for 4 weeks following discontinuation of eltrombopag. 
Broj trombocita je neophodno pratiti jednom tjedno tijekom 4 tjedna nakon prestanka uzimanja eltrombopaga.